Australian Leukaemia Study Group Myeloma II: a randomized trial of intensive combination chemotherapy with or without interferon in patients with myeloma

Douglas Joshua(Royal Prince Alfred Hospital), David Goldstein(Prince of Wales Hospital)

British Journal of Haematology

April 1, 1997

10.1046/j.1365-2141.1997.9942643.x

Cited by 35

Related Papers

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors

|Journal for ImmunoTherapy of Cancer|2023|38